- Home
- FRAF vs AARD Comparison
FRAF vs AARD Comparison
Compare FRAF & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRAF
- AARD
- Stock Information
- Founded
- FRAF 1906
- AARD 2017
- Country
- FRAF United States
- AARD United States
- Employees
- FRAF N/A
- AARD N/A
- Industry
- FRAF Major Banks
- AARD Biotechnology: Pharmaceutical Preparations
- Sector
- FRAF Finance
- AARD Health Care
- Exchange
- FRAF Nasdaq
- AARD Nasdaq
- Market Cap
- FRAF 165.3M
- AARD 154.9M
- IPO Year
- FRAF N/A
- AARD 2025
- Fundamental
- Price
- FRAF $38.81
- AARD $10.42
- Analyst Decision
- FRAF
- AARD Strong Buy
- Analyst Count
- FRAF 0
- AARD 4
- Target Price
- FRAF N/A
- AARD $31.50
- AVG Volume (30 Days)
- FRAF 17.7K
- AARD 68.3K
- Earning Date
- FRAF 04-29-2025
- AARD 01-01-0001
- Dividend Yield
- FRAF 3.35%
- AARD N/A
- EPS Growth
- FRAF N/A
- AARD N/A
- EPS
- FRAF 2.63
- AARD N/A
- Revenue
- FRAF $71,310,000.00
- AARD N/A
- Revenue This Year
- FRAF N/A
- AARD N/A
- Revenue Next Year
- FRAF N/A
- AARD N/A
- P/E Ratio
- FRAF $14.78
- AARD N/A
- Revenue Growth
- FRAF 5.24
- AARD N/A
- 52 Week Low
- FRAF $25.90
- AARD $4.88
- 52 Week High
- FRAF $40.76
- AARD $19.58
- Technical
- Relative Strength Index (RSI)
- FRAF 62.77
- AARD N/A
- Support Level
- FRAF $38.24
- AARD N/A
- Resistance Level
- FRAF $39.48
- AARD N/A
- Average True Range (ATR)
- FRAF 0.72
- AARD 0.00
- MACD
- FRAF -0.04
- AARD 0.00
- Stochastic Oscillator
- FRAF 25.57
- AARD 0.00
About FRAF Franklin Financial Services Corporation
Franklin Financial Services Corp is a bank holding company based in the United States. It is engaged in general commercial, retail banking and trust services normally associated with community banks. It offers a broad range of banking services to businesses, individuals, and governmental entities which includes accepting and maintaining cheques, savings, and time deposit accounts, providing investment and trust services, making loans and providing safe deposit facilities. The bank also performs personal, corporate, pension and fiduciary services through its Investment and Trust Services Department.
About AARD Aardvark Therapeutics Inc. Common Stock
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.